Dopavision develops a technology called MyopiaX® aimed at slowing the progression of myopia in children and adolescents through selective ocular light stimulation. The company focuses on addressing a public health issue related to myopia.

Dopavision

Fedorov Restore Vision Clinic provides treatments to improve vision loss from optic nerve lesions and retinitis pigmentosa. The clinic offers an interdisciplinary approach combining ophthalmology and neurology.

Fedorov Restore Vision Clinic

Caterna offers a digital therapy for children with amblyopia, allowing treatment at home through specific online games designed to stimulate eye function. The product is a medically certified treatment developed at TU Dresden.

Caterna

Perfood enables people to treat and prevent diseases with their diet, supported by digital solutions.

Perfood

Dopavision | 1,442 followers on LinkedIn. Everyone deserves to see the world clearly through healthy eyes. | At Dopavision, our mission is to bring a new perspective to the world of eye care by developing an innovative and widely accessible myopia intervention. By addressing a massive global public health problem, we aim to empower as many people as possible to build a healthier, brighter future.

MyopiaX is our transformative approach designed to slow the progression of myopia (nearsightedness) in children and adolescents.

Game Designer - Neurogaming, Games for Health, VR/AR, Storytelling, x-Chief Game Designer at Google

Noah Falstein

Product Lead @ Easy Bites App | Game Thinking inspired Product Leader

Kevyn Eva Norton

CEO Dopavision

Mark Wuttke

Healthcare Venture Capital

Rana Lonnen

We're excited to announce the completion of all clinic visits for the MyopiaX-1 trial, with the final visit taking place on October 4th. This marks a major milestone for everyone involved, and we couldn't be happier to share this update! This achievement reflects years of hard work, and the entire team at Dopavision extends our heartfelt thanks to everyone who made this possible—especially our clinical trial sites, participants, and their families and caregivers. As we wrap up this phase, we extend our deepest thanks for your support, which has brought us into this exciting new stage of MyopiaX’s clinical development. #myopia #clinicaltrial #research

🌍 Today marks World Sight Day, an important occasion to raise awareness about eye health as a significant global public health issue. This year spotlights the critical importance of prioritizing child eye health, giving children everywhere the opportunity to love their eyes. World Sight Day serves as an annual reminder of the necessity to make eye care accessible, available, and affordable for everyone. 👀 At Dopavision , we recognize the profound impact that early eye care can have on a child's long-term eye health and their ability to reach their full potential. With 450 million children globally having a sight condition that needs treatment and myopia (nearsightedness) a leading cause of vision impairment, our commitment to developing an accessible, child-friendly solution to control juvenile-onset myopia has never been stronger. 🔍 To learn more about the International Agency for the Prevention of Blindness (IAPB) , World Sight Day, and the "Love Your Eyes" campaign, click here: https://lnkd.in/eNGA4Dz3 #WorldSightDay #LoveYourEyes #Myopia #EyeCare

Dopavision presented key data from its MyopiaX-1 clinical trial at the 19th International Myopia Conference in Sanya, China. Friday’s presentation, delivered by Prof. Ian Flitcroft, D.Phil, FRCOphth, Coordinating Investigator of the MyopiaX-1 trial (NCT04967287), marked the first public disclosure of the 6-month clinical data in children with myopia in Europe. MyopiaX demonstrated an excellent safety profile and positive proof of concept at six months, showing promise for future clinical studies. Continue reading the full press release here: https://lnkd.in/g5vwyB2s #IMC2024 #Myopia #Innovation #PressRelease

📣 We’re excited to announce our 6-month clinical trial data for MyopiaX will be presented at the 19th International Myopia Conference. This marks a major milestone for Dopavision and we’re honored to share key insights from our MyopiaX-1 trial (NCT04967287) at such a significant forum in the myopia research community. ✈️ Meanwhile, our team is on the way to Sanya for the conference and can't wait to connect with the leading minds in myopia research. Throughout IMC 2024, Mark Wuttke , Gabriela Burian , Ida Zündorf, PhD and Nikita Wong will be present to discuss the latest advancements and innovations shaping the future of myopia control. 🗓 Mark Your Calendars: Join us on September 27th in the Pharmacological interventions session for our presentation on the MyopiaX-1 trial. Safe travels to all attending – see you in Sanya! #IMC2024 #ClinicalResearch #Myopia #Innovation

This past Wednesday, our CEO, Mark Wuttke , represented Dopavision at the Ophthalmology Futures Retina Forum, as part of the company showcase. In addition to presenting Dopavision's latest progress, Mark also participated as a panelist in the insightful session: Drugs Vs Non-Pharmacologic Therapies for Slowing Myopia Progression. We are thrilled to be involved in such discussions and contributing to driving innovation in myopia control with MyopiaX, bringing a new perspective to the world of eye care. #Ophthalmology #Innovation #Myopia #EyeCare

This year has been pivotal for the development of MyopiaX, our transformative approach that aims to slow the progression of myopia. Our Product team has been hard at work, conducting extensive usability testing with children and their families to optimize MyopiaX for real-world use. Our goal is to provide an innovative alternative for myopia control that is engaging and easy to integrate into daily routines. Here's a snapshot of what we've accomplished: 🔍 Conducted 2+ user testing sessions with young participants and their families. 🗣️ Engaged with over 20 users to ensure our device is accessible and easy to use for all. 📊 Collected insights that have directly influenced our product roadmap. We are grateful for the invaluable feedback from our participants and their families, whose input has been instrumental in shaping the future of MyopiaX. A big thank you to the teams at Südblick Augenzentren • OP - Prinz 25 Makula & Dry Eye Center, including Tímea Katona , and Praxis BeyondEye for their crucial support in recruiting participants and hosting our user testing sessions. #innovation #productdevelopment #usertesting #myopia

We're excited to announce that Dopavision has moved! Amidst the activities around the 6-month readout of our proof-of-concept clinical trial for MyopiaX and navigating a busy congress season, we've found a new home on the banks of the Spree in Berlin. Our new address is more than just an office; it's a space designed to foster collaboration and support the incredible work our team does every day. We're excited about the memories we'll create here and the opportunities this beautiful space brings. #team #innovation #collaboration

We often talk about MyopiaX, our game-changing approach to slow the progression of myopia, but we recognize it can be challenging to visualize how an active treatment delivered via a smartphone app comes to life. That's why we've created this short video - to give you a glimpse into the future of myopia control. Watch below and share your thoughts with us! #MyopiaX #Dopavision #Innovation #Myopia

Dopavision was recently featured in a Nature news article discussing the role of outdoor time in the current myopia epidemic. Our targeted light-based intervention, MyopiaX, and ongoing clinical trial (NCT04967287) were highlighted as part of the effort to address this growing challenge. Check out the full article to learn more about the crucial role light plays in myopia development and progression. 🔗 https://lnkd.in/g7BPbbjQ #myopia #science #innovation #research

Dopavision today announced topline results from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). The six-month outcomes of the randomized, controlled trial demonstrate the safety and tolerability of MyopiaX. Over six months, treatment with MyopiaX shows signals of clinical effect on the rate of myopia progression. The outcomes of the MyopiaX-1 trial add to the growing body of scientific evidence supporting MyopiaX’s mechanism of action and its potential therapeutic application to slow myopia progression. 🔗 https://lnkd.in/gcpYktHN #myopia #innovation #clinicalresearch #eyecare

Metric
Company Name	Dopavision	Fedorov Restore Vision Clinic	Caterna	Perfood
Symbol
MSH ID	COM:DOPAVISION	COM:RESTOREVISIONCLINIC	DE:CATERNA	DE:PERFOOD
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical Technology	Medical Services	Digital Health	Digital Health
Country	DE	DE	DE	DE
Stage
Employee Count
Website	dopavision.com	restorevisionclinic.com	caterna.de	perfood.de
LinkedIn	dopavision	fedorov-restore-vision-clinic	caterna	perfood-gmbh
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DOPA

COM:DOPAVISION

Dopavision

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue